Sign In
Buy ADAP
$0.0549
+0 (+0%)
At Close: Feb 20, 2026
Why Adaptimmune Therapeutics Stock Is Bolting Higher Today
10:16am, Tuesday, 07'th Sep 2021
A major licensing deal with cancer giant Roche is pushing the biotech's shares higher this morning.
Adaptimmune Stock Moves Higher On Cancer Deal With Genentech
09:08am, Tuesday, 07'th Sep 2021
Adaptimmune Therapeutics plc (NASDAQ: ADAP) has announced a collaboration and license agreement with Genentech, a unit of Roche Holdings AG (OTC: RHHBY), to develop and commercialize allogeneic
- Combining both companies' cell therapy leadership and expertise, the collaboration covers the research and development of “off-the-shelf” cell therapies for up to five shared cancer targets and
Adaptimmune (ADAP) Presents Data on Liver Cancer Candidate
12:17pm, Monday, 06'th Sep 2021
Adaptimmune (ADAP) announces encouraging data from an early-stage study on liver cancer patients from its cell therapy candidate.
Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical Benefit
06:15am, Sunday, 05'th Sep 2021
- One complete response, and a disease control rate of 64% with stable disease for ≥16 weeks in two patients, as of the data cutoff -
Why Adaptimmune Therapeutics Stock Is Spiking Today
01:38pm, Monday, 23'rd Aug 2021
The hunt for the next biotech buyout play is apparently underway.
Implied Volatility Surging for Adaptimmune Therapeutics (ADAP) Stock Options
11:26am, Monday, 16'th Aug 2021
Investors need to pay close attention to for Adaptimmune Therapeutics (ADAP) stock based on the movements in the options market lately.
Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q2 2021 Results - Earnings Call Transcript
10:44pm, Monday, 09'th Aug 2021
Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q2 2021 Results - Earnings Call Transcript
Adaptimmune to Report Q2 2021 Financial Results and Business Update on Monday, August 9, 2021
08:11am, Wednesday, 28'th Jul 2021
PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 28, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and
Why Adaptimmune Therapeutics Stock Sank in the First Half of 2021
10:00am, Monday, 19'th Jul 2021
The biotech's shares have definitely lost their shine in 2021.
Dollar General, HP, Johnson & Johnson and More Friday Afternoon Analyst Calls
12:21pm, Friday, 28'th May 2021
With the trading day more than halfway over, the markets were moving higher going into the weekend.
Why Adaptimmune Therapeutics Crushed the Market Today
05:49pm, Thursday, 20'th May 2021
A key pipeline drug performs well in a mid-stage clinical trial.
Adaptimmune's Stock Trades Higher As TCR Therapy Shows Initial Durability In Soft Tissue Cancer Settings
06:32am, Thursday, 20'th May 2021
Adaptimmune Therapeutics plc (NASDAQ: ADAP) revealed initial data from its Phase 2 SPEARHEAD-1 trial evaluating afamitresgene autoleucel (afami-cel, formerly ADP-A2M4). Data will be presented at
Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune's Phase 2 SPEARHEAD-1 Trial
05:00pm, Wednesday, 19'th May 2021
- Data will support BLA filing for afamitresgene autoleucel next year -
Adaptimmune's HiT Program Can Potentially Kill Human Tumor Cells, Animal Study Shows
12:32pm, Tuesday, 11'th May 2021
Adaptimmune Therapeutics plc (NASDAQ: ADAP) has reported first preclinical data from its HiT targeting mesothelin (a tumor-associated antigen), being co-developed with Astellas Pharma (OTCMKTS:
